Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18839049 | 0.88 | MAPK3 (0.37) | MAPK1MAPK3KCNH2NUAK1CCNE1 | |
| SCHEMBL18839050 | 0.88 | MAPK3 (0.37) | MAPK1MAPK3KCNH2NUAK1CCNE1 | |
| SCHEMBL18839128 | 0.88 | MAPK3 (0.37) | MAPK1MAPK3KCNH2NUAK1CCNE1 | |
| SCHEMBL23607768 | 0.86 | MAPK3 (0.34) | MAPK1MAPK3KCNH2NUAK1CCNE1 | |
| SCHEMBL18839061 | 0.85 | MAPK1 (0.34) | MAPK1MAPK3KCNH2NUAK1CCNE1 | |
| SCHEMBL18839063 | 0.85 | MAPK1 (0.34) | MAPK1MAPK3KCNH2NUAK1CCNE1 | |
| SCHEMBL29862434 | 0.85 | PIM1 (0.32) | MAPK1MAPK3KCNH2NUAK1CCNE1 | |
| SCHEMBL18839101 | 0.77 | MAPK1 (0.36) | MAPK1MAPK3KCNH2 | |
| SCHEMBL29862468 | 0.73 | MAPK3 (0.36) | MAPK1MAPK3KCNH2NUAK1CCNE1 | |
| SCHEMBL18131287 | 0.72 | MAPK1 (0.41) | MAPK1MAPK3KCNH2NUAK1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017080979-A1 | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-05-18 | — | — | WO | disclosed |